Synthomer will sell its Czech Acrylate Monomers business to Mutares, advancing portfolio simplification and strengthening its specialty chemicals focus.
Synthomer plc has entered into a definitive agreement to sell Synthomer a.s., the company that operates its Acrylate Monomers business in the Czech Republic, to Mutares SE & Co. KGaA. Mutares is a publicly listed German investment firm specializing in acquiring and transforming businesses undergoing periods of transition and restructuring.
The Acrylate Monomers business is recognized as one of the leading suppliers of acrylic acid and related acrylic monomers within the European merchant market. The operation employs approximately 300 people and is centered at its production facility in Sokolov, Czech Republic. In addition to serving external customers, the site plays an important role in supporting Synthomer’s own downstream manufacturing activities. It supplies acrylic monomers to several Synthomer businesses and also manufactures acrylic dispersions on behalf of the Group. These commercial and supply relationships are expected to remain in place following completion of the transaction, ensuring continuity for customers and internal operations.
Currently operating under Synthomer’s Health & Protection and Performance Materials division, the Acrylate Monomers business serves markets that are known for their cyclical nature and volatility. The business is also among the most capital-intensive operations within Synthomer’s portfolio, requiring substantial ongoing investment to maintain production capabilities and competitiveness. As the company has worked to refine its strategic direction, Acrylate Monomers has increasingly been viewed as non-core to Synthomer’s long-term objectives.
The divestment aligns with the strategic review announced by Synthomer in October 2022, during which the company identified opportunities to simplify its business structure and focus on higher-value specialty chemical segments. Acrylate Monomers represented the final remaining upstream chemicals operation within the Group, making its sale a significant milestone in the company’s transformation journey.
By completing this transaction, Synthomer expects to reduce its exposure to cyclical base chemical markets while improving the overall quality of its earnings and cash generation profile. The move is anticipated to strengthen the company’s focus on specialty chemicals, a segment characterized by higher margins, stronger growth prospects, and greater opportunities for innovation and customer differentiation. The streamlined portfolio is expected to enhance operational efficiency and support the company’s ambition to create a more resilient and sustainable business model.
Commenting on the agreement, Synthomer Chief Executive Officer Michael Willome described the sale as another important step in the execution of the company’s long-term strategy. He emphasized that Synthomer is continuing to simplify its operations while sharpening its focus on specialty chemical markets where it maintains strong competitive positions and sustainable leadership.
Willome also expressed confidence that the transaction delivers a positive outcome for all stakeholders involved. He noted that Mutares possesses extensive experience in supporting and transforming industrial businesses and has a strong track record of successfully guiding companies through periods of change. As a result, he believes Mutares is well positioned to help Acrylate Monomers continue its development and pursue future growth opportunities under new ownership.
He concluded by acknowledging the contributions of the employees within the Acrylate Monomers business and extended his best wishes to the team as they begin the next phase of their journey under Mutares’ stewardship.
Market Impact: The sale of Synthomer’s Acrylate Monomers business to Mutares is expected to have a limited immediate impact on product availability because the Sokolov facility will continue operating and existing supply agreements with Synthomer’s downstream businesses will remain intact. As a result, the supply of acrylic acid, acrylic monomers, and acrylic dispersions to the European market is unlikely to face any short-term disruption.
For chemical commodities tracked by ChemAnalyst, the near-term price impact is expected to be largely neutral. Products such as Acrylic Acid, Butyl Acrylate (BA), Ethyl Acrylate (EA), 2-Ethylhexyl Acrylate (2-EHA), and Acrylic Emulsions/Dispersions should continue to see stable supply conditions, preventing any immediate price spikes. However, the transaction reflects a broader industry trend of major chemical producers divesting commodity and upstream assets to focus on higher-margin specialty chemicals.
In the medium to long term, Mutares may implement operational restructuring, cost optimization, or strategic investments to improve profitability. Any future production rationalization or capacity adjustments could tighten regional supply and provide upward support to acrylic monomer prices in Europe. Additionally, increased consolidation within the European acrylics sector could strengthen producer pricing power.
Overall, the deal is mildly bullish for the European acrylic value chain over the long run, but with production continuity assured, ChemAnalyst-tracked acrylic commodities are expected to experience minimal immediate price volatility following the announcement.
